Project Grant R01MH139578
- The National Institute of Mental Health awarded Icahn School of Medicine at Mount Sinai $717,688 on May 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to investigate molecular and epigenetic mechanisms by which postpartum stress interacts with parity to influence vulnerability to perinatal and postpartum mood and anxiety disorders. The recipient will use a parity-by-postpartum-stress mouse model to examine how stress dysregulates dopamine responsiveness via projections...
- The National Institute of Mental Health awarded the University of Alabama at Birmingham $409,750 on March 15, 2026, under the Mental Health Research Grants program (CFDA 93.242) to determine the role of localized dopamine signals in learning. The research uses two-photon microscopy and genetically encoded sensors to simultaneously track dopamine release and neuronal activity in real-time as mice perform a neuroprosthetic control task. The work investigates whether dopamine shapes learning at the...
- The National Institute of Mental Health awarded New York University $771,272 on March 15, 2026, under the Mental Health Research Grants program (CFDA 93.242) to investigate neuroplasticity of the human maternal brain during pregnancy and its relationship to perinatal mood and anxiety disorders (PMADs). The research examines trajectories of brain structural and functional changes across pregnancy, the role of brain iron in maternal neuroplasticity and PMAD symptoms, and associations between...
- The National Institute of Mental Health awarded the University of Virginia $234,660 on September 28, 2025, under the Mental Health Research Grants program (CFDA 93.242) to investigate epigenetic biomarkers, negative valence symptomatology, and hypothalamic-pituitary-adrenal (HPA) axis dysfunction as mechanisms underlying risk for postpartum depression. The research examines two estrogen-responsive epigenetic biomarkers at established risk loci for postpartum depression and their relationship...
- The National Institute of Mental Health awarded the University of Alabama at Birmingham $1.809 million on June 5, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop novel preclinical models of neuroHIV that incorporate antiretroviral therapy suppression dynamics. The award funds development of next-generation neuroHIV models composed of autologous peripheral human immune cells, relevant human glial cell types, and an intact blood-brain barrier in the context of...
- The National Institute of Mental Health awarded Yale University $838,378 on March 10, 2026, under the Mental Health Research Grants program (CFDA 93.242) to investigate the neural circuits regulating infant social behaviors and learning, with focus on somatostatin-expressing neurons in the zona incerta (ZISST neurons) in preweaning mice. The research comprises three aims. Aim 1 will determine activity dynamics of ZISST neurons in response to maternal behaviors using fiber photometry and...
- The National Institute of Mental Health awarded The Johns Hopkins University $384,245 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop DNA probes and modified extracellular vesicles as therapeutic tools to reverse stress-induced epigenetic changes in the brain. The project addresses the role of chronic stress and cortisol exposure in causing epigenetic modifications that disrupt genes critical for brain function and neurodevelopment, contributing to...
- The National Institute of Mental Health awarded the University of Alabama at Birmingham $786,444 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop an artificial intelligence-based decision support system for predicting and preventing return emergency department visits among mental health patients. The project will develop a large language model system to automatically extract mental health emergency department return risk factors from clinical notes,...
- The National Institute of Mental Health awarded The Pennsylvania State University $659,846 on April 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to investigate epigenetic mechanisms underlying stress-enhanced fear learning in male and female mice. The research examines the role of histone deacetylase 3 (HDAC3) and histone acetylation in regulating how acute stress establishes a molecular memory in the amygdala that gates sensitivity to subsequent fear conditioning....
- The National Institute of Mental Health awarded $1,488,310 to the University of North Carolina at Chapel Hill on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to evaluate personalized aperiodic transcranial alternating current stimulation as a treatment for antenatal depression. The research project, titled "Personalized Aperiodic Transcranial Alternating Current Stimulation as a Treatment for Antenatal Depression" (R61MH144538), develops and tests...
The National Institute of Mental Health awarded the University of Alabama at Birmingham $616,868 on August 12, 2026, under the Mental Health Research Grants program (CFDA 93.242) to investigate neural circuit mechanisms underlying postpartum social cognitive impairment induced by adolescent stress. The recipient will develop and deploy a mouse model to explore how early life stress—specifically mild social isolation during late adolescence—affects postpartum behaviors and cognition. The research focuses on the longitudinal pathway from adolescent stress through pregnancy and delivery to postpartum psychiatric changes, including mood alterations, social cognitive deficits, and parenting impairment. The study will functionally and transcriptionally investigate how elevated and sustained plasma corticosterone levels alter neuronal function and produce behavioral deficits during the first postpartum week, with particular attention to glucocorticoid receptor mechanisms. The model demonstrates that stress-exposed female mice show no significant behavioral or hormonal changes at baseline or during pregnancy, but exhibit sustained corticosterone elevation and behavioral changes by postpartum day 7 that mirror patterns observed in postpartum depression patients. Preliminary work shows that blocking glucocorticoid receptors during the early postpartum period improves behavioral outcomes, highlighting the hormone's causal role in stress-related postpartum pathology. The award carries a period of performance from August 12, 2026, through May 31, 2031. Work is performed in Birmingham, Alabama.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $616.9k | 8/14/26 |